psoriatic/psoriatic arthritis aggravated/psoriatic reaction was continuing to spread, primary location was lower legs; guttate psoriasis; primary immunization : unknown manufacturer, at least one was non- pfizer vaccine and booster: comirnaty; primary immunization : unknown manufacturer, at least one was non- pfizer vaccine and booster: comirnaty; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency (ra). regulatory number: gb-mhra-webcovid-202202160841217200-rtlxw (ra). other case identifier(s): gb-mhra-adr 26609188 (ra). a 62 year-old female patient received bnt162b2 (comirnaty), administration date 12nov2021 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "trigeminal neuralgia" (unspecified if ongoing); "psoriatic arthritis" (unspecified if ongoing); "osteoarthritis" (unspecified if ongoing); "fibromyalgia" (unspecified if ongoing); "gerd" (unspecified if ongoing); "immunodeficiency" (unspecified if ongoing), notes: has an illness or condition, not listed above, which reduces the immune response; "high blood pressure" (unspecified if ongoing); "laryngopharyngeal reflux" (unspecified if ongoing), notes: lpr. patient had not had symptoms associated with covid-19. the patient's concomitant medications were not reported. vaccination history included: covid 19 vaccine (dose 2; manufacturer unknown), for covid-19 immunisation; covid 19 vaccine (dose 1; manufacturer unknown), for covid-19 immunisation. the following information was reported: off label use (medically significant), interchange of vaccine products (medically significant) all with onset 12nov2021, outcome "unknown" and all described as "primary immunization : unknown manufacturer, at least one was non- pfizer vaccine and booster: comirnaty"; psoriatic arthropathy (medically significant), outcome "not recovered", described as "psoriatic/psoriatic arthritis aggravated/psoriatic reaction was continuing to spread, primary location was lower legs"; guttate psoriasis (medically significant) with onset 27nov2021, outcome "not recovered", described as "guttate psoriasis". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative. the clinical course was reported as follows: as of 16feb2022, psoriatic reaction was continuing to spread, primary location was lower legs. the patient had not been tested positive for covid-19 since having the vaccine. patient was not enrolled in clinical trial. this report was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected